Key Points
- Insider selling: CFO Sara Bonstein sold 1,447 shares on Jan. 8 at an average of $174.17 (≈$252,024) and also sold shares on Jan. 6–7, while multiple executives sold roughly $15.29M of company stock across Jan. 6–8, trimming the CFO's stake by 1.77%.
- Financials and stock move: INSM opened at $170.27 and was down 3.3%; the company reported revenue up 52.4% year-over-year but missed EPS estimates and still posts a large negative net margin and negative return on equity.
- Catalysts and risks: Management set key clinical readouts (ENCORE topline expected Mar/Apr 2026, CEDAR in Q2 2026) and started new Phase‑3 programs, but faces investor litigation and execution/near-term spending risk; analysts' consensus is a "Moderate Buy" with a $205.64 average target.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) insider Michael Alexander Smith sold 709 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $175.07, for a total value of $124,124.63. Following the sale, the insider owned 58,090 shares in the company, valued at approximately $10,169,816.30. This trade represents a 1.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Michael Alexander Smith also recently made the following trade(s):
- On Thursday, January 8th, Michael Alexander Smith sold 1,053 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $183,401.01.
- On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $241,968.68.
- On Monday, November 3rd, Michael Alexander Smith sold 27,130 shares of Insmed stock. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40.
Insmed Stock Down 3.3%
Shares of NASDAQ INSM opened at $170.27 on Friday. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75. The firm's 50-day simple moving average is $190.31 and its 200 day simple moving average is $151.37. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The company has a market cap of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08.
Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same period in the prior year, the firm posted ($1.27) earnings per share. The company's revenue was up 52.4% on a year-over-year basis. On average, research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research firms have recently commented on INSM. Leerink Partners reissued an "outperform" rating on shares of Insmed in a research note on Thursday, December 18th. Mizuho set a $212.00 price objective on Insmed in a report on Thursday, December 18th. UBS Group reduced their target price on shares of Insmed from $223.00 to $215.00 and set a "buy" rating on the stock in a research note on Tuesday. Morgan Stanley set a $157.00 price target on shares of Insmed in a research report on Thursday. Finally, Guggenheim cut their price objective on shares of Insmed from $230.00 to $221.00 and set a "buy" rating on the stock in a report on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Insmed has an average rating of "Moderate Buy" and an average price target of $205.64.
Get Our Latest Research Report on Insmed
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Insmed by 13.0% in the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company's stock worth $2,870,957,000 after acquiring an additional 2,291,328 shares in the last quarter. Norges Bank bought a new position in shares of Insmed during the 2nd quarter valued at about $194,728,000. Artisan Partners Limited Partnership increased its stake in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company's stock worth $711,076,000 after purchasing an additional 1,623,342 shares in the last quarter. Orbis Allan Gray Ltd acquired a new stake in Insmed during the 2nd quarter worth approximately $153,389,000. Finally, Darwin Global Management Ltd. lifted its stake in Insmed by 5.8% in the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company's stock valued at $2,897,797,000 after buying an additional 1,112,824 shares in the last quarter.
More Insmed News
Here are the key news stories impacting Insmed this week:
- Positive Sentiment: Company update: Insmed reported strong unaudited revenues tied to its commercial launches—BRINSUPRI posted roughly $144.6M in total revenue in its first full quarter and ~$172.7M for full-year 2025; ARIKAYCE generated ~ $433.8M for 2025, exceeding the top end of prior guidance. Management provided 2026 ARIKAYCE guidance of $450M–$470M, signaling continued commercial momentum. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
- Neutral Sentiment: Pipeline timing: Management updated clinical timelines — ENCORE (ARIKAYCE Phase 3) topline now expected March/April 2026 and CEDAR (brensocatib Phase 2b in HS) topline anticipated in Q2 2026. These upcoming readouts are material catalysts but the shifted timing may compress near-term volatility. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
- Neutral Sentiment: New Phase‑3 starts: Insmed initiated the PALM‑ILD Phase 3 for TPIP in PH‑ILD in Q4 2025 and plans further Phase 3 studies in PAH, PPF and IPF in 2026 — a positive R&D cadence but one that increases near-term spend and execution risk. Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
- Neutral Sentiment: Media attention: Jim Cramer flagged Insmed as "worth keeping an eye on," which can boost retail interest and liquidity but is not a fundamental endorsement. Jim Cramer on Insmed
- Negative Sentiment: Insider selling: Multiple executives (CEO, CFO, COO and others) have recently sold shares across Jan. 6–8, and a report flagged approximately $15.29M in insider sales—activity that can signal near-term profit-taking or create negative perception among investors. Insider Selling: Insmed Insider Sells $15,293,208.00 in Stock
- Negative Sentiment: Investor litigation alert: Pomerantz LLP launched an investor investigation related to Insmed, which introduces potential legal and reputational risk and could weigh on sentiment until clarified. Pomerantz Investigates Claims On Behalf of Investors of Insmed
About Insmed
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
